In healthcare I’ve decreased small bio positions and increased large bio and pharma that are ex US bc I think the strong dollar is a tailwind considering most generate a lot of revenue in dollars but costs are skewed towards home currency so margins are benefiting from FX (as well as reporting in home currency ) E.g. GSK
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.